Surfing the MASH Tsunami

Send us Fan Mail In a monumental moment in the never-ending pursuit of putting a major dent in Fatty Liver disease, Madrigal Pharmaceuticals announced positive topline results from the pivotal Phase 3 MAESTRO-NASH clinical trial of resmetirom for the treatment of NASH and liver fibrosis. Madrigal’s leadership intends to file for resmetirom’s accelerated approval with the FDA in the first half of 2...

Send us Fan Mail In a monumental moment in the never-ending pursuit of putting a major dent in Fatty Liver disease, Madrigal Pharmaceuticals announced positive topline results from the pivotal Phase 3 MAESTRO-NASH clinical trial of resmetirom for the treatment of NASH and liver fibrosis. Madrigal’s leadership intends to file for resmetirom’s accelerated approval with the FDA in the first half of 2...

Send us Fan Mail In a monumental moment in the never-ending pursuit of putting a major dent in Fatty Liver disease, Madrigal Pharmaceuticals announced positive topline results from the pivotal Phase 3 MAESTRO-NASH clinical trial of resmetirom for the treatment of NASH and liver fibrosis. Madrigal’s leadership intends to file for resmetirom’s accelerated approval with the FDA in the first half of 2...

Send us Fan Mail NASH-TAG 2023 co-course director Stephen Harrison and scientific advisory board committee member Jörn Schattenberg join Louise Campbell and Roger Green to preview what is shaping to be a highly anticipated conference leading the field into a promising New Year. In light of Madrigal’s announcement of positive topline results from the MAESTRO-NASH trial of resmetirom, the first half...

Send us Fan Mail Yesterday, in a monumental moment in the never-ending pursuit of putting a major dent in Fatty Liver disease, Madrigal Pharmaceuticals announced positive topline results from the pivotal Phase 3 MAESTRO-NASH clinical trial of resmetirom for the treatment of NASH and liver fibrosis. Madrigal’s leadership intends to file for resmetirom’s accelerated approval with the FDA in the firs...

Send us Fan Mail In another exciting installment of the Surfing NASH year-end interview series, Jörn Schattenberg, Louise Campbell and Roger Green are joined by Donna Cryer, founder, president and CEO of the Global Liver Institute (GLI). This conversation embodies the progressive and collaborative energy of GLI from the outset, beginning with Donna’s explanation that they now have NASH materials a...

Send us Fan Mail In this exclusive interview, Hannes Hagström joins Jörn Schattenberg, Louise Campbell and Roger Green to explore papers emerging from Scandinavia which offer fascinating insights to the field at large. Hannes opens the conversation with his idea that 2022 was an encouraging year for research, specifically in that the mechanisms of drugs in development “feel more realistic.” When a...

Send us Fan Mail In the Season 3 NAFLD Year-in-Review  conversations series, Surfers Jörn Schattenberg, Louise Campbell and Roger Green embark on a string of interviews with a handful of Key Opinion Leaders who made headlines and advances in Fatty Liver disease in 2022. In this exclusive segment, Scott Friedman joins to discuss his perspective on what has been an eye-opening year for liver science...

Send us Fan Mail The latter half of December marks the Surfing the NASH Tsunami annual NAFLD Year-in-Review . In Part 1 of this Season 3 finale, Surfers Jörn Schattenberg, Louise Campbell and Roger Green interview Scott Friedman, Hannes Hagström and Donna Cryer to discuss putting a dent in Fatty Liver disease in 2022 and beyond. This episode features compiled excerpts from our respective guest int...

Send us Fan Mail This week, our conversation From the Vault features a special, single-interview episode to give listeners a chance to learn about Jörn Schattenberg in a different way as he became the permanent Key Opinion Leader on Surfing the NASH Tsunami earlier this year.  The Surfing the NASH Tsunami seasons start with the calendar year, but our first episode posted on April 15, 2020. As we e...

Send us Fan Mail This week, our conversation From the Vault features a special, single-interview episode to give listeners a chance to learn about Jörn Schattenberg in a different way as he became the permanent Key Opinion Leader on Surfing the NASH Tsunami earlier this year.  The Surfing the NASH Tsunami seasons start with the calendar year, but our first episode posted on April 15, 2020. As we e...

Send us Fan Mail Surfing the NASH Tsunami begins its year-end series to reflect on a momentous 2022 for NAFLD and Season 3 of the podcast. Leading this final conversation, Roger Green asks Jörn Schattenberg what has surfaced in the past several months with the various consortia, and particularly the retrospective analysis in NAIL-NIT. Jörn starts by commenting that non-invasive testing may have mo...

Send us Fan Mail Surfing the NASH Tsunami begins its year-end series to reflect on a momentous 2022 for NAFLD and Season 3 of the podcast. In this conversation, Surfers Jörn Schattenberg, Louise Campbell and Roger Green continue to share their respective highlights. Louise and Jörn begin by discussing some of the benefits of FibroScan in terms of how practitioners have come to use data more approp...

Send us Fan Mail Surfing the NASH Tsunami begins its year-end series to reflect on a momentous 2022 for NAFLD and Season 3 of the podcast. In this conversation, Surfers Jörn Schattenberg, Louise Campbell and Roger Green share their respective highlights. All three agree that a return to in-person meetings offered both opportunities to reconnect and meet for the first time those who have been part...

Send us Fan Mail Surfers Jörn Schattenberg, Louise Campbell and Roger Green host the Season 3, Year-in-Review episode to reflect on major themes and takeaways from a momentous 2022 in NAFLD. The trio begin by highlighting the rewarding return to in-person conferences and events, and meeting fellow surfers for the first time offline. In response to his stepping into the role of permanent co-host, J...

Send us Fan Mail Lars Johannson’s 2021 Paris NASH presentation, “Innovations in Imaging Assessment of Fibrosis“,” introduced his audience to a dynamic, multidimensional view of tools that can show us how the liver works. His viewpoint combined with discussion on novel imaging tools and approaches creates an episode From the Vault that might leave you repeatedly thinking “Oh, Wow!”  This conversati...

Send us Fan Mail The Liver Forum aims to advance the regulatory sciences for the treatment of NAFLD/NASH and liver fibrosis by providing a neutral, independent venue for ongoing multi-stakeholder dialogue. Their work facilitates the best science-based decisions on how to study efficacy and safety in real-time by using collective knowledge and experience with therapies for advancing liver disease....

Send us Fan Mail The Liver Forum aims to advance the regulatory sciences for the treatment of NAFLD/NASH and liver fibrosis by providing a neutral, independent venue for ongoing multi-stakeholder dialogue. Their work facilitates the best science-based decisions on how to study efficacy and safety in real-time by using collective knowledge and experience with therapies for advancing liver disease....

Send us Fan Mail Previously, Executive Director Veronica Miller explained how she arrived to the field of NAFLD and the history of the Liver Forum. This conversation begins with recollections from Manal Abdelmalek and Jörn Schattenberg on their respective introductions to the Liver Forum. Before the collaborative space existed, Manal points out that when industry first began to ponder NASH drugs t...

Send us Fan Mail The Liver Forum aims to advance the regulatory sciences for the treatment of NAFLD/NASH and liver fibrosis by providing a neutral, independent venue for ongoing multi-stakeholder dialogue. Their work facilitates the best science-based decisions on how to study efficacy and safety in real-time by using collective knowledge and experience with therapies for advancing liver disease....

Send us Fan Mail The Liver Forum aims to advance the regulatory sciences for the treatment of NAFLD/NASH and liver fibrosis by providing a neutral, independent venue for ongoing multi-stakeholder dialogue. Their work facilitates the best science-based decisions on how to study efficacy and safety in real-time by using collective knowledge and experience with therapies for advancing liver disease....

Send us Fan Mail This episode From the Vault follows Season 2, Episode 43 in discussing the possible role of NASH cirrhosis clinical trials in the transition from biopsy as gold standard to a post-biopsy world. Terns Pharma CEO Sen Sundaram joins this conversation from the audience to ask whether the term “cirrhosis” is medically helpful or might warrant replacement with “end stage liver disease.”...

Send us Fan Mail Surfing the NASH Tsunami hosts its first episode dedicated to nutrition and NASH with distinguished guest, Prof. Shira Zelber-Sagi. Alongside this rich discussion are Ken Cusi, Jörn Schattenberg, Louise Campbell and Roger Green. This final conversation starts with Jörn  recalling Shira's statement that “diet is every day.” He notes that for patients whose serious medical issu...

Send us Fan Mail Surfing the NASH Tsunami hosts its first episode dedicated to nutrition and NASH with distinguished guest, Prof. Shira Zelber-Sagi. Surfing alongside this rich discussion are Ken Cusi, Jörn Schattenberg, Louise Campbell and Roger Green. Ken begins this conversation by extending his ideas around the need for US insurance companies to support integrated solutions. Louise asks Ken wh...

Send us Fan Mail Surfing the NASH Tsunami hosts its first episode dedicated to nutrition and NASH with distinguished guest, Prof. Shira Zelber-Sagi. Surfing alongside this rich discussion are Ken Cusi, Jörn Schattenberg, Louise Campbell and Roger Green. Roger prompts this conversation by stating that everyone eventually makes poor dietary choices. The group agrees through various examples that the...